Cytokinetics reports Q1 2026: MYQORZO net product rev $4.8M, net loss $206M; ACACIA-HCM meets endpoints

CYTOKINETICS INC

2026-Q1 EPS reported -$1.67 revenue$19,355,000

MYQORZO net product revenue $4.8M for ~9 weeks; total revenue $19.4M (incl $11.9M milestone from Bayer).
Net loss $206.0M ($1.67/sh) vs $161.4M loss in Q1 2025; cash $1.1B (down $144M from Dec 2025).
ACACIA-HCM met dual primary endpoints (KCCQ and peak VO2) in non-obstructive HCM; full results at upcoming medical congress.
Over 275 HCPs prescribed MYQORZO to ~680 patients in Q1; European Commission approved for oHCM.
FY 2026 GAAP combined R&D and SG&A guidance maintained at $830M-$870M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CYTOKINETICS INC reported first quarter of 2026 results: revenue $19.4 million.

Period: first quarter of 2026
Revenue: $19.4 million
Result: reported results

Exact text from the filing

Cash, cash equivalents and investments declined by approximately $144 million during the first quarter of 2026. Revenues • Total revenues for the first quarter of 2026 were $19.4 million, compared to $1.6 million for the same period in 2025. Total revenues in the first quarter of 2026 include: o $4.8 million MYQORZO net product revenue which represents

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-206360

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.